tiprankstipranks
Advertisement
Advertisement
Tiziana fully enrolls Phase 2 placebo-controlled MS trial
PremiumThe FlyTiziana fully enrolls Phase 2 placebo-controlled MS trial
26d ago
Tiziana Life Sciences announces updated intranasal foralumab data
Premium
The Fly
Tiziana Life Sciences announces updated intranasal foralumab data
28d ago
Tiziana Life Sciences Reports Positive Expanded Access Data for Intranasal Foralumab in Progressive MS
Premium
Company Announcements
Tiziana Life Sciences Reports Positive Expanded Access Data for Intranasal Foralumab in Progressive MS
28d ago
Tiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal Foralumab
PremiumCompany AnnouncementsTiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal Foralumab
2M ago
Tiziana Life Sciences’ Intranasal Foralumab MSA Trial Highlighted in Late-Breaking Poster at 7th World Parkinson Congress
Premium
Company Announcements
Tiziana Life Sciences’ Intranasal Foralumab MSA Trial Highlighted in Late-Breaking Poster at 7th World Parkinson Congress
2M ago
Tiziana Life Sciences Reports Positive Preclinical Data for Nasal Anti-CD3 in Age-Related Cognitive Decline
Premium
Company Announcements
Tiziana Life Sciences Reports Positive Preclinical Data for Nasal Anti-CD3 in Age-Related Cognitive Decline
3M ago
Tiziana Life Sciences Raises $8.8 Million in Oversubscribed Direct Offering to Fund Phase 2 Trials
PremiumCompany AnnouncementsTiziana Life Sciences Raises $8.8 Million in Oversubscribed Direct Offering to Fund Phase 2 Trials
5M ago
Tiziana Life Sciences Raises Up to $17.6 Million in Insider-Led Direct Offering to Fund Phase 2 Trials
Premium
Company Announcements
Tiziana Life Sciences Raises Up to $17.6 Million in Insider-Led Direct Offering to Fund Phase 2 Trials
5M ago
Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering
Premium
The Fly
Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100